Pharmacokinetics and safety in cynomolgus monkeys of a monoclonal antibody targeting human scavenger receptor class B type-1 for hepatitis C treatment

Antiviral Therapy

Volumn 18, Issue 6, 2013, Pages 775-784

  Flores, M Victoria ^a,b   Corbaul, Romuald G ^a,c   Guionaud, Silvia ^a,d  

^a Pizer Inc   (United Kingdom)

^b Long Hanborough   (United Kingdom)

^c CISTIM Leuven Vzw   (Belgium)

^d MILLENNIUM PHARMACEUTICALS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY SEQ2; SCAVENGER RECEPTOR BI; UNCLASSIFIED DRUG; SCARB1 PROTEIN, HUMAN; SCAVENGER RECEPTOR B;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY BLOOD LEVEL; AREA UNDER THE CURVE; ARTICLE; BINDING AFFINITY; BLOOD CHEMISTRY; BLOOD SAMPLING; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE COMPARISON; DRUG HALF LIFE; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG SCREENING; DRUG TARGETING; FEMALE; HEPATITIS C; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MACACA FASCICULARIS; MALE; MAXIMUM PLASMA CONCENTRATION; MOUSE; NONHUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RECEPTOR OCCUPANCY; SINGLE DRUG DOSE; TIME TO MAXIMUM PLASMA CONCENTRATION; VIRUS CULTURE; ANIMAL; ANTAGONISTS AND INHIBITORS; BLOOD; BLOOD ANALYSIS; CELL LINE; CULTURE TECHNIQUE; DRUG EFFECTS; HEPACIVIRUS; LIVER; LIVER CELL; METABOLISM; PATHOLOGY; SERODIAGNOSIS; TREATMENT OUTCOME;

ANIMALS; ANTIBODIES, MONOCLONAL; BLOOD CHEMICAL ANALYSIS; CELL CULTURE TECHNIQUES; CELL LINE; FEMALE; HEPACIVIRUS; HEPATITIS C; HEPATOCYTES; HUMANS; LIVER; MACACA FASCICULARIS; MALE; MICE; NEUTRALIZATION TESTS; SCAVENGER RECEPTORS, CLASS B; TREATMENT OUTCOME;

EID: 84892380179     PISSN: 13596535     EISSN: 20402058     Source Type: Journal    
DOI: 10.3851/IMP2570     Document Type: Article

References (34)

1. National Institute for Health and Care Excellence. NICE technology appraisal guidance. TA 252. Telaprevir for the treatment of genotype 1 chronic hepatitis C. (Updated April 2012. Accepted 21 October 2013.) Available from http://publications.nice.org.uk/telaprevir-for-the-treatment-ofgenotype-1- chronic-hepatitis-c-ta252
2. NICE technology appraisal guidance. TA 253. Boceprevir for the treatment of genotype 1 chronic hepatitis C. (Updated April 2012. Accepted 21 October 2013.) Availablefrom http://publications.nice.org.uk/boceprevir-for- thetreatment-of-genotype-1-chronic-hepatitis-c-ta253
3. Sarrazin C, Zeuzem S. Resistance to direct antiviral agents in patients with hepatitis C virus infection. Gastroenterology 2010; 138:447-462
4. Hézode C, Forestier N, Dusheiko G, et al. Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. N Engl J Med 2009; 360:1839-1850
5. McHutchison JG, Everson GT, Gordon SC, et al. Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. N Engl J Med 2009; 360:1827-1838
6. Brimacombe CL, Grove J, Meredith LW, et al. Neutralizing antibody resistant hepatitis C virus cell-to-cell transmission. J Virol 2011; 85:596-605
7. Timpe JM, Stamataki Z, Jennings A, et al. Hepatitis C virus cell-cell transmission in hepatoma cells in the presence of neutralizing antibodies. Hepatology 2008;47:17-24
8. Ploss A, Evans MJ, Gaysinskaya VA, et al. Human occludin is a hepatitis C virus entry factor required for infection of mouse cells. Nature 2009; 457:882-886
9. Evans MJ, von Hahn T, Tscherne DM, et al. Claudin-1 is a hepatitis C virus co-receptor required for a late step in entry. Nature 2007; 446:801-805
10. Syder AJ, Lee H, Zeisel MB, et al. Small molecule scavenger receptor BI Antagonists are potent HCV entry inhibitors. J Hepatol 2011; 54:48-55
11. McKelvy J, Lee H, Syder AJ, et al. ITX 5061, an orally bioavailable,clinical stage compound, targets scavenger receptor BI to inhibit HCV entry. 16th International symposium on hepatitis C virus and related viruses. 3-7 October 2009, Nice, France. Abstract 0-61
12. Masson D, Koseki M, Ishibashi M, et al. Increased HDL cholesterol and ApoA-I in humans and mice treated with a novel SR-BI inhibitor. Arterioscler Thromb Vasc Biol 2009; 29:2054-2060
13. Wong-Staal F, Syder AJ, McKelvy JF. Targeting HCV entry for development of therapeutics. Viruses 2010; 2:1718-1733
14. Catanese MT, Ansuini H, Graziani R, et al. Role of scavenger receptor class B type I in hepatitis C virus entry: kinetics and molecular determinants. J Virol 2010; 84:34-43
15. Cortese R, Luzzago A, Nicosia A, et al. inventors; Istituto di Ricerche di Biologia Molecolare P. Angeletti S.p.A., assignee. Antigen binding protein directed against scavenger receptor B1 that inhibit HCV replication. World Intellectual Property Organization Patent WO2006/005465. 2006 January 191
16. Meuleman P, Catanese T, Verhoye L, et al. A human monoclonal antibody targeting scavenger receptor class B type I precludes hepatitis C virus infection and viral spread in vitro and in vivo. Hepatology 2012; 55:364-372
17. Rigotti A, Trigatti B, Babitt J, et al. Scavenger receptor BI a cell surface receptor for high density lipoprotein. Curr Opin Lipidol 1997; 8:181-188
18. Van Eck M, Twisk J, Hoekstra M, et al. Differential effects of scavenger receptor BI deiciency on lipid metabolism in cells of the arterial wall and in the liver. J Biol Chem 2003;278:23699-23705
19. Trigatti BL, Krieger M, Rigotti A. Inluence of the HDL receptor SR-BI on lipoprotein metabolism and atherosclerosis. Arterioscler Thromb Vasc Biol 2003; 23:1732-1738
20. Hoekstra M, Meurs I, Koenders M, et al. Absence of HDL cholesteryl ester uptake in mice via SR-BI impairs an adequate adrenal glucocorticoid-mediated stress response to fasting. J Lipid Res 2008; 49:738-745
21. Cai L, Ji A, de Beer FC, et al. SR-BI protects against endotoxemia in mice through its roles in glucocorticoid production and hepatic clearance. J Clin Invest 2008; 118:364-375
22. Acton S, Osgood D, Donoghue M, et al. Association of polymorphisms at the SR-BI gene locus with plasma lipid levels and body mass index in a white population.Arterioscler Thromb Vasc Biol 1999 19:1734-1743
23. Hsu LA, Ko YL, Wu S, et al. Association between a novel 11-base pair deletion mutation in the promoter region of the scavenger receptor class B type I gene and plasma HDL cholesterol levels in Taiwanese Chinese. Arterioscler Thromb Vasc Biol 2003; 23:1869-1874
24. Vergeer M, Korporaal SJA, Franssen R, et al. Genetic variant of the scavenger receptor BI in humans. N Engl J Med 2011; 364:136-145
25. Kato T, Date T, Murayama A, et al. Cell culture and infection system for hepatitis C virus. Nat Protoc 2006; 1:2334-2339
26. Wakita T, Pietschmann T, Kato T, et al. Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. Nat Med 2005; 11:791-796
27. Catanese MT, Graziani R, von Hahn T, et al. High-avidity monoclonal antibodies against the human scavenger class B type I receptor eficiently block hepatitis C virus infection in the presence of high-density lipoprotein. J Virol 2007;81:8063-8071
28. Grove J, Nielsen S, Zhong J, et al. Identiication of a residue in hepatitis C virus E2 glycoprotein that determines scavenger receptor BI and CD81 receptor dependency and sensitivity to neutralizing antibodies. J Virol 2008; 82:12020-12029
29. Rigotti A, Trigatti BL, Penman M, et al. A targeted mutation in the murine gene encoding the high density lipoprotein (HDL) receptor scavenger receptor class B type I reveals its key role in HDL metabolism. Proc Natl Acad Sci U S A 1997; 94:12610-12615
30. Rigotti A, Miettinen HE, Krieger M. The role of the highdensity lipoprotein receptor SR-BI in the lipid metabolism of endocrine and other tissues. Endocr Rev 2003; 24:357-387
31. Barter PJ, Brewer HB, Jr., Chapman MJ, et al. Cholesteryl ester transfer protein: A novel target for raising HDL and inhibiting atherosclerosis. Arterioscler Thromb Vasc Biol 2003; 23:160-167
32. Out R, Hoekstra M, Spijkers JAA, et al. Scavenger receptor class B type I is solely responsible for the selective uptake of cholesteryl esters from HDL by the liver and the adrenals in mice. J Lipid Res 2004; 45:2088-2095
33. Illingworth DR, Lees AM, Lees RS. Adrenal cortical function in homozygous familial hypercholesterolemia. Metabolism 1983; 32:1045-1052
34. Tabrizi M, Funelas C, Suria H. Application of quantitative pharmacology in development of therapeutic monoclonal antibodies. AAPS J 2010; 12:592-601